Jennifer M Llewelyn from 13 Thornberry Ln, Hockessin, DE 19707, age 55, Phone: 302 478-4136

Jennifer Llewelyn Phones & Addresses

13 Thornberry Ln, Hockessin, DE 19707 • 302 478-4136
2105 Largo Rd, Wilmington, DE 19803
Tallahassee, FL
Saint Peters, MO

Work

Company:

Dupont
Jan 2013 to Aug 2016
Position:

Manager

Education

Degree:

Doctorates, Doctor of Philosophy
School / High School:

Florida State University
1996 to 2000
Specialities:

Philosophy, Chemistry

Skills

Analytical Chemistry • Chemistry • Technology Transfer • Pharmaceutical Industry • Hplc • Chromatography • R&D • Lc Ms • Cross Functional Team Leadership • Pharmaceutics • Spectroscopy • Research and Development • Mass Spectrometry • High Performance Liquid Chromatography • Validation • Organic Chemistry • Glp • Uv/Vis • Formulation • Good Laboratory Practice • U.s. Food and Drug Administration • Fda • Sop • Uv/Vis Spectroscopy

Industries

Pharmaceuticals

Us Patents

Extended Release Formulations Comprising Quetiapine And Methods For Their Manufacture
view source
US Patent:

20110319383, Dec 29, 2011
Filed:

Nov 16, 2007
Appl. No.:

12/599861
Inventors:

Daniel Brown - Wilmington DE, US
Donna Caster - Wilmington DE, US
Brian Clark - Cheshire, GB
Sandra Hopkins - Wilmington DE, US
Jennifer Llewelyn - Wilmington DE, US
Lisa Martin - Wilmington DE, US
Elizabeth Meehan - Cheshire, GB
Robert Timko - Wilmington DE, US
Husheng Yang - Wilmington DE, US
Assignee:

ASTRAZENECA AB - Sodertalje
International Classification:

A61K 31/554
A61P 25/18
US Classification:

51421113
Abstract:

The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed.

Extended Release Compositions And Methods For Their Manufacture
view source
US Patent:

20080287418, Nov 20, 2008
Filed:

Nov 14, 2007
Appl. No.:

11/939585
Inventors:

Daniel Brown - Wilmington DE, US
Donna Caster - Wilmington DE, US
Brian Clark - Macclesfield, GB
Sandra Hopkins - Wilmington DE, US
Jennifer Llewelyn - Wilmington DE, US
Elizabeth Meehan - Macclesfield, GB
Lisa Martin - Wilmington DE, US
Robert Timko - Wilmington DE, US
Husheng Yang - Wilmington DE, US
Assignee:

ASTRAZENECA AB - Sodertalje
International Classification:

A61K 31/554
A61P 25/18
US Classification:

51421113
Abstract:

Extended release formulations of quetiapine and its pharmaceutically salts, and methods for manufacture of the formulations, may include the use of polymers selected for their physical and chemical characteristics. The formulations may include polymers selected to cause solid dosage forms of the formulations to conform to preselected quetiapine release criteria. The formulations may include non-polymer materials that may affect quetiapine release.

Resumes

Senior Director, Analytical Development

view source

Location:

Newark, DE

Industry:

Pharmaceuticals

Work:

Dupont Jan 2013 - Aug 2016
Manager
Incyte Jan 2013 - Aug 2016
Senior Director, Analytical Development
Dupont Oct 2010 - Dec 2012
Principal Investigator
Astrazeneca Nov 2000 - Oct 2010
Senior Scientist

Education:

Florida State University 1996 - 2000
Doctorates, Doctor of Philosophy, Philosophy, Chemistry Lindenwood University 1993 - 1996
Bachelors, Bachelor of Science, Chemistry

Skills:

Analytical Chemistry
Chemistry
Technology Transfer
Pharmaceutical Industry
Hplc
Chromatography
R&D
Lc Ms
Cross Functional Team Leadership
Pharmaceutics
Spectroscopy
Research and Development
Mass Spectrometry
High Performance Liquid Chromatography
Validation
Organic Chemistry
Glp
Uv/Vis
Formulation
Good Laboratory Practice
U.s. Food and Drug Administration
Fda
Sop
Uv/Vis Spectroscopy